Sulfacetamide formulations for treatment of rosacea
View Patent ↗A method for treating rosacea in a patient comprising administering to a patient suffering from rosacea a first topical composition comprising at least one sulfacetamide or a derivative thereof and at least one sunscreen, wherein the administration of said first composition provides a more effective treatment of said rosacea in comparison to treatment of rosacea achieved by administration of a second topical composition comprising metronidazole.
1. A method for treating rosacea in a patient comprising administering to a patient suffering from rosacea a first topical composition comprising at least one sulfacetamide or a derivative thereof and at least one sunscreen, wherein the administration of said first composition provides a more effective treatment of said rosacea in comparison to treatment of rosacea achieved by administration of a second topical composition comprising metronidazole.
2. The method of claim 1 , wherein the second topical composition comprising metronidazole consists essentially of metronidazole.
3. The method of claim 1 , wherein, in the second topical composition comprising metronidazole, metronidazole is the sole active ingredient.
4. The method of claim 1 , wherein the second topical composition comprises about 0.75% metronidazole.
5. The method of claim 1 , wherein said increased treatment of rosacea results in a higher decrease of inflammatory lesions in said patient in comparison to that achieved by said administration of said second topical composition comprising metronidazole.
6. The method of claim 5 , wherein administration of said first topical composition provides at least an 8% higher decrease of inflammatory lesions in said patient in comparison to that achieved by said administration of said second topical composition.
7. The method of claim 1 , wherein said increased treatment of rosacea results in a higher decrease of erythema in said patient in comparison to that achieved by said administration of said topical composition comprising metronidazole.
8. The method of claim 7 , wherein administration of said first topical composition provides at least a 24% higher decrease of erythema in said patient in comparison to that achieved by said administration of said second topical composition.
9. The method of claim 1 , wherein said increased treatment is measured after at least 12 weeks of treatment with said topical compositions.
10. The method of claim 1 , wherein said administration comprises administering said topical compositions to said patient each day during a period of treatment.
11. The method of claim 1 , wherein said administration comprises intermittent administration of said topical compositions.
12. The method of claim 1 , wherein said sulfacetamide is sodium sulfacetamide.
13. The method of claim 1 , wherein said first composition comprises about 5 to about 15% by weight of said at least one sulfacetamide or a derivative thereof.
14. The method of claim 1 , wherein said first topical composition further comprises sulfur.
15. The method of claim 14 , wherein said first topical composition comprises about 2.5 to about 10% by weight of said sulfur.
16. The method of claim 1 , wherein said first composition comprises at least two different sunscreens.
17. The method of claim 1 , wherein said sunscreen is selected from the group consisting of avobenzone, octocrylene, octyl methoxycinnamate, oxybenzone, titanium dioxide, zinc oxide, and mixtures thereof.
18. The method of claim 1 , wherein said first composition comprises about 0.1 to about 10% by weight of said at least one sunscreen.
19. The method of claim 1 , wherein said at least one sunscreen is present in an amount sufficient to produce a sun protection factor of at least 2.
20. A method for treating inflammatory lesions in a patient comprising administering to a patient suffering from inflammatory lesions a first topical composition comprising at least one sulfacetamide or a derivative thereof and at least one sunscreen, wherein the administration of said first composition results in a higher decrease of inflammatory lesions in said patient in comparison to that achieved by administration of a second topical composition comprising metronidazole.
21. The method of claim 20 , wherein the second topical composition comprising metronidazole consists essentially of metronidazole.
22. The method of claim 20 , wherein, in the second topical composition comprising metronidazole, metronidazole is the sole active ingredient.
23. The method of claim 20 , wherein the second topical composition comprises about 0.5% to about 1.5% metronidazole.
24. The method of claim 20 , wherein administration of said first topical composition provides at least an 8% higher decrease of inflammatory lesions in said patient in comparison to that achieved by said administration of said second topical composition.
25. The method of claim 20 , wherein said decrease of inflammatory lesions is measured after at least 12 weeks of treatment with said topical compositions.
26. The method of claim 20 , wherein said administration comprises twice daily administration of said topical composition to said patient.
27. A method for treating erythema in a patient comprising administering to a patient suffering from erythema a first topical composition comprising at least one sulfacetamide or a derivative thereof and at least one sunscreen, wherein the administration of said first composition results in a higher decrease of erythema in said patient in comparison to that achieved by administration of a second topical composition comprising metronidazole.
28. The method of claim 27 , wherein the second topical composition comprising metronidazole consists essentially of metronidazole.
29. The method of claim 27 , wherein, in the second topical composition comprising metronidazole, metronidazole is the sole active ingredient.
30. The method of claim 27 , wherein the second topical composition comprises about 0.5% to about 1.5% metronidazole.
31. The method of claim 27 , wherein administration of said first topical composition provides at least a 24% higher decrease of erythema in said patient in comparison to that achieved by said administration of said second topical composition.
32. The method of claim 27 , wherein said decrease of erythema is measured after at least 12 weeks of treatment with said topical compositions.
33. The method of claim 27 , wherein said administration comprises at least once a day administration of said topical composition to said patient during the treatment regimen.
34. The method of claim 1 , wherein said administration comprises twice daily administration of said topical composition to said patient.
35. The method of claim 10 , wherein said period of treatment comprises a sufficient period of time to observe a reduced incidence of said rosacea.
36. The method of claim 10 , wherein said period of treatment is from about 6 to about 12 weeks.
37. The method of claim 10 , wherein said patient is intermittently administered said topical composition after said period of treatment.
38. The method of claim 11 , wherein said intermittent administration is conducted when said patient commences said treatment, as said treatment is in its final stages, or as part of a maintenance regimen.
39. The method of claim 11 , wherein said intermittent administration comprises administration of said topical compositions to said patient more than once per week but less than once per day.
40. The method of claim 1 , wherein said sunscreen blocks the absorption of UV radiation.
41. The method of claim 1 , wherein said sunscreen absorbs UV A and UV B radiation.
42. The method of claim 1 , wherein said sunscreen is an inorganic oxide.
43. The method of claim 1 , wherein said first topical composition further comprises benzyl alcohol.